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Estrogen and inflammation: hormone generous action
spreads to the brain
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As direct targets of pharmaceuticals, estrogen receptors
represent an attractive biological system for the dis-
covery of potent, selective and specific drugs to control
the evolution of selected disorders.1 In addition, their
endogenous ligands, estrogens, were proved to faith-
fully fulfill the denomination of endocrine agents: the
recent past featured a boost of novel physiological tar-
gets outside the hypothalamic-pituitary-ovary axis, the
system where the action of sex hormones was believed
to be restricted. To date, it appears that almost any
tissue and cell in the human body is attracted by the
fascinating power of estrogen, particularly the brain. A
large body of studies points to a potential beneficial
role of estrogens in different brain pathologies, as
proved by epidemiological, experimental and animal
model data after the natural or surgical ablation of
estrogen synthesis. The role of estrogens in depression
has been hypothesized for quite a long time based on
the observation that decreased plasma levels of these
molecules during the menstrual phase, after parturition
or at menopause are often associated with mood dis-
orders. Epidemiological studies have also suggested
the involvement of hormonal factors in multiple scler-
osis (MS): increased levels of sex hormones during
pregnancy have been shown to associate with signifi-
cant reduced severity of MS, whereas clinical symp-
toms often exacerbate postpartum, when sex hormone
levels are remarkably reduced. Similarly, post-meno-
pausal administration of estrogens may delay the onset
of Alzheimer’s disease (AD) in elderly women and
ameliorate Parkinson’s tremors. More recently, the
comparison of the different age profile in the manifes-
tation of psychotic episodes in the two sexes with the
levels of circulating estradiol in normal and schizo-
phrenic patients led to hypothesize a role for this hor-
mone also in this CNS disorder.
Because of the diverse etiology of these diseases, the
comprehension of the mechanism underlying estrogen
beneficial action is puzzling. This issue is even more
complex if we consider that hormone positively affects
other pathophysiologic processes, such as osteo-
porosis, atherosclerosis and stroke.
Is there a common mechanistic denominator in all
of these diseases which might underlie the widespread
favorable effect of estrogens?
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Inflammation has always been associated with the
manifestation of MS and recent findings have under-
lined how the onset and progression of neurodegener-
ative diseases correlate with the existence of a local
ongoing inflammatory reaction. Evidence has been pro-
vided that major depression associates with activation
of the inflammatory response system and that antide-
pressants may reduce the interferon-/IL-10 ratio, rais-
ing the question whether changes in the immune sys-
tem and depression are causal or co-incidental effects.2
AD and cerebral ischemia are also associated with elev-
ated expression of cytokines, adhesion molecules and
other inflammatory molecules.3,4 Finally, increased
levels of inflammatory cytokines were reported in psy-
chiatric patients, revealing a potential role of these
compounds also in schizophrenia.5 On the other hand,
the role of inflammation in the pathogenesis of osteo-
porosis and atherosclerosis is well documented. As a
consequence, the reduction of the inflammatory
component is the aim of different therapeutic inter-
ventions or a beneficial complementary effect of drugs,
used to cure these diseases.
Thus, an intriguing hypothesis to explain estrogen
beneficial effects in so many and diversified human
pathologies would be the existence of a link between
hormone action and the machinery sustaining the
inflammatory response.
Because of their well-known effect on ovarian fol-
licle maturation, an inflammatory-like reaction, estro-
gens were considered more as pro- rather than anti-
inflammatory agents. However, besides the well estab-
lished positive effects of sex hormones in selected
pathologies with a relevant inflammatory component,
such as MS and osteoporosis, there is now a wealth
of experimental models where the lack of endogenous
estrogens facilitates the onset of inflammation that is
antagonized by estrogen replacement. Examples of
such models are: carrageenan-induced pleurisy, endo-
toxin-induced uveitis, experimental encephalomyelitis
and adjuvant-induced arthritis and cutaneous wound
healing.6–8 In all of these models estradiol clearly
opposes the inflammatory process.
Different biological mechanisms underlying estrogen
anti-inflammatory activity have been proposed.
Adhesion and migration of leukocytes through the
endothelium of the vascular system are hampered by
estradiol, as shown by the decrease in the expression
of adhesion molecules (such as E-selectin, cadherins
and CAM) and chemokines (such as the monocyte
chemoattractant protein-1, MCP-1). A reduced syn-
thesis in proteolytic enzymes might also account for
estrogen reduction of tissue degradation and inflam-
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mation; proteases abundantly and specifically secreted
by macrophages, such as cathepsins K and L involved
in bone resorption, or matrix metalloproteinase-9
(MMP-9) implicated in matrix homeostasis and cell
infiltration, are inhibited by estrogen receptor acti-
vation. Extensive work on estrogen action in bone
remodeling demonstrated that the estrogen protective
role in inflammatory processes also occurs by blocking
resident inflammatory cell production of proinflam-
matory cytokines (IL-1, IL-6 and TNF-), hematopoietic
growth factors (macrophage colony stimulating factor,
M-CSF) and cell differentiation agents (receptor acti-
vator of NF-kB ligand, RANKL). Therefore, inhibition
of the synthesis of these potent inflammatory mediators
has been proposed to explain the detrimental effects of
estrogen deficiency on the human skeletal system at
menopause. Consistently with this hypothesis, estra-
diol has been shown to oppose the inflammatory reac-
tion occurring in carrageenan-induced pleurisy by
blocking the synthesis of proinflammatory mediators,
such as IL-6, TNF- and iNOS. The inhibitory regu-
lation of estradiol on the synthesis of iNOS induced
by inflammatory stimuli has been observed in several
cellular and biological systems, suggesting a primary
role for this pathway in estrogen biological activity.
Since macrophages play an essential role in the
inflammatory process, the positive effect of estrogen on
inflammation-related diseases could be mediated by
suppressing monocyte recruitment and/or macrophage
activation at the inflammatory site.
Microglia, the resident immune cells in the brain,
play a pivotal role in immune surveillance, host
defense and tissue repair in the CNS. In response to
brain injury or immunological challenges, microglia
readily become activated as characterized by morpho-
logical changes, expression of surface antigens and pro-
duction of immune modulators.9 The precise function
of activated microglia and their secretory products
remains controversial. The initial phase of microglia
response aimed at inducing phagocytosis has relevance
in sustaining neuron viability, removing toxic cellular
debris and promoting tissue repair and is a critical
event in the resolution of the inflammatory attack. On
the other hand, a persistent state of microglia activation
has been hypothesized to have negative effects of neu-
ron viability. Microglia activation is in fact a histo-
pathological hallmark of several neurodegenerative
diseases, including Parkinson’s disease, AD, MS, AIDS
dementia, Huntington, Sandhoff disease and Lewy
bodies dementia, suggesting its cytotoxic potential.
These observations led us to hypothesize that a chronic
inflammatory reaction, driven mainly by reactive
microglia, may contribute to the process of neuronal
loss and matrix destruction observed in these chronic
disorders.
Recently, two groups have independently shown
that estradiol has a strong influence on microglia
activity.10,11 Estrogen in fact opposes the morphologi-
cal and biochemical activation of microglia induced by
the bacterial endotoxin lipopolysaccharide (LPS). This
effect, observed in primary cultures of rat microglia
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with very low concentration of 17-estradiol, is dose-
dependent and blocked by specific ER antagonists.
These observations, together with the finding that cells
must be challenged with hormone for a few hours in
order to become irresponsive to LPS, suggest that a
receptor-mediated mechanism is involved. Indeed, rt-
PCR and immunocytochemical studies reported in
these recent papers show the presence of high concen-
trations of ER and ER in microglia, in agreement
with previous reports on receptor expression in mono-
blastoid and macrophage cells.12
Existing evidence on estrogen activity in ‘in vivo’
models of CNS inflammatory disorders are still scarce,
albeit the investigations made so far on experimental
autoimmune encephalomyelitis (EAE) and ischemic
damage are in line with the hypothesis of an anti-
inflammatory role of estrogens. EAE is an inflammatory
demyelinating disease of the CNS induced by immun-
izing susceptible strains of laboratory rodents with
myelin proteins or peptides and is a model that con-
siderably contributed to gain insights into the patho-
genesis of MS. In this model, gender difference in the
susceptibility and severity parallel gender differences
reported in MS and treatment with low doses of 17-
estradiol (comparable with diestrus levels) signifi-
cantly reduced the severity of EAE by decreasing the
number and size of inflammatory and demyelinated
foci and the secretion of pro-inflammatory cytokines,
while augmenting the secretion of anti-inflammatory
cytokines (IL-10); ovariectomy, conversely, caused sig-
nificantly more severe EAE. Estrogens were also shown
to be protective in case of ischemic damage in different
models of CNS injury. It has been proposed that estro-
gens exert part of their protective effects by preventing
reperfusion associated with permanent brain damage,
which produces an influx of oxygen followed by an
accumulation of oxygen-derived free radicals; estradiol
attenuates the peroxidative damage and iNOS induc-
tion.
In the last few years several experimental reports
have shown that estrogens protect against brain
degeneration by directly targeting neurons.13 The
recent findings on estrogen-dependent attenuation of
microglia response provide a novel explanation for
hormone action in the brain and for the understanding
of the neurodegenerative process in neural pathologies,
like MS, AD or ischemic brain damage, in which
inflammation plays a relevant role, and eventually also
in schizophrenia or depression, where suggestive evi-
dence indicates their association with local inflam-
mation.
An interesting issue of both biological and pharma-
ceutical relevance is the unraveling of the molecular
players influenced by estradiol in the inflammatory
plot. The primary targets of estradiol action within
responsive cells are the two well-described receptors
(ER- and ER-) which are hormone-regulated tran-
scription factors. Hormone-activated receptors can
induce or repress transcription, in a cell and promoter
context-dependent manner, through the interaction
with multisubunit complexes containing coactivator
News & Commentary
238
Molecular Psychiatry
and/or corepressor functions. Many observations have
indicated that estradiol directly inhibits the expression
of pro-inflammatory genes via a receptor-mediated
mechanism, in spite of the lack of canonical estrogen
responsive elements in the promoter region of these
genes. Because of the capability of hormone-activated
ERs to interact with other classes of transcription fac-
tors coupled to membrane receptor signaling molecules
(such as Sp-1, Jun/Fos, NF-kB and Stat), it is postulated
that estrogen-dependent inhibition of transcription
occurs without a physical interaction of the ligand-
receptor complex with the proinflammatory gene pro-
moters. The receptor could in fact alter the dynamics
of the association of other transcription factors with the
transcription machinery (a mechanism known as
transrepression). This would be reminiscent of the
mechanism evoked for the glucocorticoid receptor (GR)
and the peroxisome proliferator activated receptors
(PPAR)  and , which also have been shown to inhibit
macrophage activation and production of pro-inflam-
matory cytokines at the level of transcription.
Alternatively, transrepression could be the result of
the competition between NRs and other classes of tran-
scription factors for limiting amounts of general coacti-
vators, such as CREB-binding protein (CBP) and p300,
or for NR specific activators such as steroids receptor
coactivator-1 (SRC-1). Recent findings have suggested
that recruitment of complexes bearing histone deace-
tylase activity provides a critical step in the process
of transrepression by NRs; thus, inhibition of histone
acetylation could represent an additional level of con-
trol of pro-inflammatory gene expression.14 Future
research will be devoted toward the understanding of
whether and which of these mechanisms hold true for
the ER anti-inflammatory activity.
ER knock-out animal models have demonstrated
that, at least in the brain and vascular wall, the selec-
tive activation of the -isoform is responsible for
mediating the protective effects of estrogen. However,
nongenomic actions accounting for rapid effects both
in the onset and duration have been described and
associated with an estrogen receptor lining in the
plasma membrane; limited existing information on this
receptor structure and on the relative signal transduc-
tion pathway have however hampered the understand-
ing of the biological and pharmacological implications.
It is too early to think of estrogen as a truly anti-
inflammatory pill; however, it is tempting to speculate
on its potency and mechanism of action. Would estro-
gen stand the comparison with cortisone, the proto-
typic anti-inflammatory compound acting through
NRs? A comparison between the activity of these two
classes of drugs would have relevant biomedical conse-
quences, in both the acute treatment of infections
(feminine secondary effects are null here) and in
chronic preventive therapies (for which active indus-
trial effort is elaborating ER drugs at their third gener-
ation as tissue-specific selective estrogen receptor
modulators, or SERMs). A SERM is a molecule that
binds with high affinity to the ER and has tissue-spe-
cific effects distinct from estradiol, acting as an estro-
gen agonist in some tissues and as an antagonist in
others. The development of SERMs that selectively
interact with specific receptors in specific tissues offers
the possibility of improving the risk/benefit profile of
hormone replacement therapy and perhaps even
extending the use of these analogues to men, for whom
the usefulness of estrogen therapy has been limited by
its potential feminizing effects. Academic, industrial
and public attention is devoted towards the future
expansion and innovations in the selective modulation
of ER to prevent chronic diseases and promote heal-
thy aging.
At menopause, the ovarian synthesis of estrogen is
over and women face the possibility of living the last
third of their life with mild or severe menopausal syn-
drome. At best, some will experience mucosal (vaginal)
atrophy and vasomotor disturbance; others do carry the
risk of developing a chronic disabling or disqualifying
disease, making the choice of hormone replacement
therapy more critical. By extending also to the brain,
the prodigious activity of estrogen has brought high
expectations as to the beneficial role of hormone in the
preventive therapy and health of the aging women.
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